Leerink has upgraded Gilead Sciences (GILD) to outperform, citing the growth outlook for its PrEP medication lenacapavir for ...

Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from ...

Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...

In a report released yesterday, David Risinger from Leerink Partners reiterated a Buy rating on Roivant Sciences (ROIV – Research ...

Analysts at Leerink Partnrs lifted their FY2025 EPS estimates for shares of Opthea in a report released on Tuesday, October ...

Research analysts at Leerink Partnrs cut their Q3 2024 earnings per share (EPS) estimates for Biohaven in a report released ...

Leerink Partners has maintained its Market Perform rating and $4.00 price target for Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX). The firm acknowledged the encouraging new HELIOS open-label data ...

Leerink Partners analysts are forecasting annual sales of $866 million in 2026, compared to a consensus of $362 million. The ...

Leerink assumed coverage of Mind Medicine with an Outperform rating and $20 price target The firm likes the emerging ...

Leerink Partners has maintained its Market Perform rating and $4.00 price target for Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX). The firm acknowledged the encouraging new HELIOS open-label data for ...

Leerink analyst Marc Goodman assumed coverage of Stoke Therapeutics with an Outperform rating and $18 price target The firm ...